Enhanced expression of the adhesion markers CD29, CD49c, CD56, CD63 and CD107a on CD45− melanoma cells and loss of T-cell-related immunity is implicated in melanoma progression following a prolonged period in which metastatic disease has remained clinically silent/undetected. Here, CD63 is linked to melanoma.